Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

RVC and Evgen Pharma to explore treatment for osteoarthritis
Researchers will investigate the potential of the drug SFX-01 as a treatment for osteoarthritis.
Work will build on a previous collaboration

The RVC and Evgen pharma have secured funding from the Biotechnology and Biological Sciences Research Council (BBSRC) for a four-year PhD studentship focused on investigating treatment for osteoarthritis.

The Industrial Co-operative Awards in Science & Technology (CASE) PhD Studentship will allow researchers to investigate the potential of the drug SFX-01 as a treatment for the disease, which affects almost 9 million people across the UK.

The work will build on a previous collaboration, which showed that mice with spontaneously-arising osteoarthritis demonstrated significantly improved bone architecture and preservation of normal movement following three months of SFX-01 treatment.

Professor Andrew Pitsillides, who led the study, said: “Myself and my colleagues Drs Isabel Orriss and Behzad Javaheri in the RVC’s Skeletal Biology Group are very excited by the prospect of working with Evgen Pharma to identify the cellular and molecular targets by which SFX-01 exerts its beneficial actions in osteoarthritis.”

Evgen Pharma is a clinical stage drug development company that focuses on the treatment of cancer and neurological conditions.

CEO Dr Stephen Franklin commented: “As a Company, we remain focused on the delivery of our current Company sponsored clinical trials and our strategic focus is in cancer and neurology. 

“We will, however, provide SFX-01 to a limited number of world leading academics and clinical groups that wish to investigate SFX-01 in alternative therapeutic areas if they can demonstrate a robust clinical plan, source their own non-dilutive grant funding and we retain commercialisation rights.

“We, and the RVC, are delighted that the BBSRC is funding this programme and it is another step towards the possibility of a future, grant funded, clinical trial on SFX-01 in osteoarthritis”. 

Become a member or log in to add this story to your CPD history

Reporting service for dead wild birds updated

News Story 1
 The Animal and Plant Health Agency (APHA) has updated its online reporting service for dead wild birds.

The new version allows those reporting a dead bird to drop a pin on a map when reporting the location. It also includes a wider range of wild bird species groups to select from when describing the bird.

The online service, which helps APHA to monitor the spread of diseases such as avian influenza, can be accessed here

Click here for more...
News Shorts
King Charles becomes patron of The Kennel Club

The Kennel Club has announced that King Charles has become its latest patron, continuing a long-standing royal tradition.

His patronage follows the support of the late Queen Elizabeth II, who was patron from 1952, the year of her coronation, until her death in 2022.

The Kennel Club has received royal support since it began in 1873, when it received support from Prince Edward, then Prince of Wales. When he ascended to the throne in 1901, King Edward began a tradition of the head of state offering their patronage.

Tony Allcock, Kennel Club Chairman, said: "We are delighted and most honoured that His Majesty the King will continue the tradition of royal support for The Kennel Club and help us in our mission in making a positive difference for dogs and their owners."